Technology in Cancer Research & Treatment最新文献

{"title":"FTIR Spectroscopy Analysis of Bound Water in Dried Saliva Samples: Differentiation of Smoking and Non-Smoking Groups and Implications for Oral Cancer Risk.","authors":"Maria Clara Coelho Ferreira, Vitórya Carvalho Pádua de Magalhães, Thayná Melo de Lima Morais, Felipe Peralta, Pedro Arthur Augusto Castro, Denise Maria Zezell, Marcelo Saito Nogueira, Luis Felipe Cs Carvalho","doi":"10.1177/15330338251317304","DOIUrl":"10.1177/15330338251317304","url":null,"abstract":"<p><p><b>Background:</b> According to the WHO, oral cancer is the thirteenth most common cancer worldwide, with tobacco use being one of the primary causes of oral cancer. This study aimed to characterize and differentiate the saliva and bound water using FTIR spectroscopy in smoking and non-smoking individuals. <b>Materials and Methods:</b> This prospective observational study analyzed dried saliva samples from control, smoking, and occasional smoking groups using an attenuated total reflectance Fourier Transform Infrared (ATR-FTIR) spectrometer. The high wavenumber spectral region of 2800-3600 cm-¹ was selected for analysis. <b>Results:</b> The results indicate that standard variance normalization (SNV) reduced intragroup variability and highlighted differences in smokers' spectra within the 3250-3500 cm-¹ region, associated with the absorption of water bound to saliva molecules. Cubic SVM models using SNV spectra demonstrated higher classification accuracy between groups, achieving 15.6% greater sensitivity and 1.3% lower specificity compared to models based on the second-order derivative. RUSBoosted Trees addressed data imbalances, enhancing both sensitivity and specificity. The study suggests that spectral changes may reflect salivary biochemistry linked to smoking and potentially to oral cancer risk. <b>Conclusions:</b> We conclude that differentiation between normal individuals and smokers can be achieved using high wavenumber FTIR spectral analysis. Additionally, we demonstrate the relationship between bound water molecules and salivary biomolecules in control, smoking, and occasional smoking groups. This technique has potential applications in elucidating OH vibrations within biological systems.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251317304"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089716/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144094631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Orosomucoid 1 is a Potential Prognostic Biomarker for Uterine Sarcoma.","authors":"Dan Yuan, Yue Huang, Ying Cai, Chi Zhang, Jin-Jing Wang, Jian-Guo Zhou","doi":"10.1177/15330338251343487","DOIUrl":"10.1177/15330338251343487","url":null,"abstract":"<p><p>IntroductionUterine sarcoma (US) is a rare tumor characterized by high aggressiveness, a tendency for recurrence and distant metastasis, and an extremely poor prognosis. In this study, we evaluated the expression of Orosomucoid 1 (ORM1) in different subtypes of US and the relationship between survival rates and clinicopathological features.MethodA retrospective study was conducted on 50 cases diagnosed with US in our hospital from 2011 to 2023. Immunohistochemistry (IHC) was used to detect the expression levels of ORM1 in different subtypes of US.The chi-square test and Kaplan-Meier survival analysis were used to analyze the relationship between ORM1 expression and clinical parameters as well as prognosis. Cox analysis was employed to evaluate the relationships between prognosis and clinical parameters in US.ResultCompared to normal proliferative endometrial tissue (NPE), the expression of ORM1 was downregulated in low-grade endometrial stromal sarcoma (LG-ESS), high-grade endometrial stromal sarcoma (HG-ESS), and undifferentiated uterine sarcoma (UUS) (P < .001,P < .001,and P < .001, respectively). Compared to normal uterine smooth muscle tissue (UNSM), the expression of ORM1 was upregulated in leiomyosarcoma (LMS) (P = .006). High ORM1 expression levels in US patients were associated with poor overall survival (OS) and progression-free survival (PFS) (P = .027 and P = .005, respectively). Multivariate COX analysis revealed that tumor stage and ORM1 expression are independent prognostic factors for US patients.ConclusionORM1 is expressed at low levels in ESS and at high levels in LMS. ORM1 potentially serve as a novel biomarker for the diagnosis, classification, and prognosis of US.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251343487"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12089707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144102682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of 3D Printing and Augmented Reality in the Management of Hepatic Malignancies.","authors":"Filippos F Karageorgos, Ion-Anastasios Karolos, Theodoros Pettas, Vassilios Tsioukas, Christos Pikridas, Georgios Tsoulfas","doi":"10.1177/15330338251323138","DOIUrl":"10.1177/15330338251323138","url":null,"abstract":"<p><p><b>Introduction:</b> 3-dimensional (3D) printing and augmented reality (AR) are emerging technologies that are used in a wide variety of scientific fields. Among them, medicine is one of the most promising fields of application since these technologies can benefit not only surgeons, but also medical/surgical trainees, patients and can potentially benefit health care systems with better educated staff working on personalized solutions for the patients. Thus, potentially reducing intra-operative and post operative complications and overall costs for the health care systems. Hepatic malignancy surgeries are some of the most demanding surgeries that could a general surgeon perform. The intra-operative and post-operative risks and complications render them demanding. In literature there are cases of research studies including applications of 3D printing and augmented reality in hepatic malignancies. <b>Methods:</b> For this, a comprehensive literature search was conducted on Scopus and Pubmed databases (latest search September 5, 2024). Research studies that included applications of 3D printing and AR in hepatic malignancies were eligible for the review. <b>Results:</b> Herein, twelve papers have been included and presented, which either include the use of 3D printing or the use of AR. There are some cases where both technologies were used simultaneously. 3D printing technology and AR can be used alone or in combination together to aid in the management of hepatic malignancies. <b>Conclusion:</b> Encouraging results (eg, efforts to reduce cost of 3D printing, proper surgical pre-planning, usefulness in education of medical personnel and patients) from the use of these technologies, not only qualitatively but also quantitatively, show that the medical staff can help patients and improve their part of the health system. Yet much more studies need to validate whether the use of these two technologies provides positive results on the surgeries or not.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251323138"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11843687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circular RNAs as Biomarkers in Breast Cancer Diagnosis, Prognosis, Molecular Types, Metastasis and Drug Resistance.","authors":"Li-Xin Li, Yun Hao, Lei Dong, Zhong-Qi Qiao, Shun-Chao Yang, Yan-Duo Chen, Kai Zhang, Ya-Wen Wang","doi":"10.1177/15330338251328500","DOIUrl":"10.1177/15330338251328500","url":null,"abstract":"<p><p>Breast cancer is one of the leading causes of cancer-related deaths in women worldwide. Circular RNAs (circRNAs), a novel class of endogenous noncoding RNA with a covalently closed continuous loop that lacks the 5'-cap structure and the 3'-poly A tail, are more stable than linear RNAs and less susceptible to degradation by nucleases. CircRNAs are widespread in multiple mammalian genomes and have been detected in various tissues, cells and body fluids. Increasing evidence shows that abnormal expression of circRNAs is involved in the development of a variety of diseases, including breast cancer. Numerous studies have explored the potential of circRNAs as biomarkers in various malignant tumors. In this review, we aim to provide a comprehensive overview of the latest advances in circRNAs as promising biomarkers in the early diagnosis, prognosis, molecular type, metastasis and drug resistance of breast cancer.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251328500"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143626079","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of the Dose-Volume Effect Parameter \"a\" in EUD-Based TCP Models for Breast Cancer Radiotherapy.","authors":"Farshid Mahmoudi, Nahid Chegeni, Ali Bagheri, Amir Danyaei, Samira Razzaghi, Shole Arvandi, Amal Saki Malehi, Bahare Arjmand, Azin Shamsi, Majid Mohiuddin","doi":"10.1177/15330338251329103","DOIUrl":"10.1177/15330338251329103","url":null,"abstract":"<p><p>IntroductionRadiotherapy treatment plans traditionally rely on physical indices like Dose-volume histograms and spatial dose distributions. While these metrics assess dose delivery, they lack consideration for the biological effects on tumors and healthy tissues. To address this, radiobiological models like tumor control probability (TCP) and Normal tissue complications probability (NTCP) are increasingly incorporated to evaluate treatment efficacy and potential complications. This study aimed to assess the predictive power of radiobiological models for TCP in breast cancer radiotherapy and provide insights into the model selection and parameter optimization.MethodsIn this retrospective observational study, two commonly used models, the Linear-Poisson and Equivalent uniform dose (EUD)-based models, were employed to calculate TCP for 30 patients. Different radiobiological parameter sets were investigated, including established sets from literature (G₁ and G₂) and set with an optimized \"a\" parameter derived from clinical trial data (a₁ and a₂). Model predictions were compared with clinical outcomes from the START trials.ResultsThe Linear-Poisson model with es lished parameter sets from the literature demonstrated good agreement with clinical data. The standard EUD-based model (a = -7.2) significantly underestimated TCP. While both models exhibited some level of independence from the specific parameter sets (G₁ vs. G₂), the EUD-based model was susceptible to the \"a\" parameter value. Optimization suggests a more accurate \"a\" value closer to -2.57 and -5.65.ConclusionThis study emphasizes the importance of clinically relevant radiobiological parameters for accurate TCP prediction and optimizing the \"a\" parameter in the EUD-based model based on clinical data (a1 and a2) improved its predictive accuracy significantly.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251329103"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11960152/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143754603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Expression Characteristics of the RBFOX1 Gene in Colorectal Cancer.","authors":"Jian Li, Youheng Wang, Jian Xu, Min Niu, Songlin Wan, Yi Liu, Zhao Ding, Guangchun Li, Qun Qian, Daojiang Li","doi":"10.1177/15330338251333695","DOIUrl":"10.1177/15330338251333695","url":null,"abstract":"<p><p>IntroductionCopy number variation is a significant characteristic of colorectal cancer progression. RBFOX1 (A2BP1) is the gene with the highest frequency of copy number loss in colorectal cancer, but current research related to it and colorectal cancer is relatively scarce.MethodsData from TCGA and other sources were used to analyze the copy number variation and mRNA expression levels of RBFOX1, as well as their correlation with clinical pathological data. Immunohistochemistry and immunofluorescence experiments were used to analyze the expression of RBFOX1 protein in colorectal cancer cells and tissues.ResultsRBFOX1 has a high frequency (22.4%) of copy number loss and diverse copy number variations in colorectal cancer tissues. High-level RBFOX1 deletion is prone to occur in the right-sided colon and tissues with high microsatellite instability. The copy number variation of RBFOX1 and mRNA expression are not correlated. In tumor tissues, RBFOX1 mRNA shows a characteristic of reduced expression, which is significantly related to BRAF mutation (P = 4.7e-05, P = 0.03). Low expression of RBFOX1 is prone to occur in the right-sided colon and tissues with high microsatellite instability. The protein encoded by RBFOX1 is expressed in normal intestinal tissues, but shows a characteristic of absence in some colorectal cancer tissues.ConclusionIn the right-sided colon and tissues with high microsatellite instability, RBFOX1 shows copy number loss and low mRNA expression. This characteristic is closely related to BRAF gene mutation, and the protein of RBFOX1 is absent in some colorectal cancer tissues.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251333695"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144111990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retraction: Potential Molecular Mechanisms of AURKB in the Oncogenesis and Progression of Osteosarcoma Cells: A Label-Free Quantitative Proteomics Analysis.","authors":"","doi":"10.1177/15330338251321913","DOIUrl":"10.1177/15330338251321913","url":null,"abstract":"","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251321913"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11938861/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143701616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bispecific c-Met/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor.","authors":"HuanRan Yang, YanJun Zhang, YanQiu Li, Shang Peng, Ran An, NaNa Du, JiaWei Cao, Fei Chu, JingTing Min","doi":"10.1177/15330338251336850","DOIUrl":"https://doi.org/10.1177/15330338251336850","url":null,"abstract":"<p><p>ObjectiveTo evaluate the killing effect of c-Met CAR-T on tumor cells with different degrees of c-Met expression. It was demonstrated that CAR-T autocrine PD-1 antibody could alleviate immune checkpoint inhibition and enhance the anti-tumor effect of T cells.MethodsThe specificity and clinical significance of c-Met and PD-L1 expression in various solid tumors were verified by bioinformatics analysis. c-Met specific CAR-T and c-Met specific CAR-T secreted by PD-L1 were synthesized, and c-Met CAR-T and c-Met/PD-1 CAR-T were prepared by constructing lentivirus. Flow cytometry was used to verify the positive rate and cell population of CAR-T, western blot was used to verify the secretion of PD-1 antibody, and cck-8 was used to detect the proliferation of CAR-T in tumor cells with different c-Met expression. LDH and ELISA further evaluated the antitumor effects of c-Met CAR-T and c-Met/PD-1 CAR-T in vitro.Resultsc-Met and PD-L1 were expressed in pancreatic cancer, ovarian cancer, esophageal cancer, bladder cancer, glioma and other tumors, and were associated with a variety of immune cell infiltration. Tumor cells with high expression of c-Met can strongly stimulate the proliferation of c-Met CAR-T, and c-Met CAR-T has strong cell lysis ability on tumor cells with high expression of c-Met. Autocrine PD-1 antibody can significantly improve the activity of c-Met CAR T cells, tumor lysis ability and cytokine secretion level.ConclusionThe antitumor activity of c-Met CAR-T is positively correlated with the expression of c-Met. c-Met CAR-T secreted by PD-1 showed enhanced antitumor function in solid tumor treatment.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251336850"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035267/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shedding Light on the Prognostic and Predictive Value of Circulating Tumor DNA for Management of Patients with Early-Stage Colon Cancer.","authors":"Rami Yanes, Turcin Saridogan, Vikram Gorantla, Abigail Overacre, Ronan W Hsieh, James Celebrezze, Tara Magge, Meghana Singhi, Anwaar Saeed, Amer H Zureikat, Arvind N Dasari, Ibrahim Halil Sahin","doi":"10.1177/15330338251317094","DOIUrl":"10.1177/15330338251317094","url":null,"abstract":"<p><p>The management of early-stage colon cancer involves surgical resection of the primary tumor with or without chemotherapy, depending on pathological staging. The benefit of adjuvant chemotherapy for stage II and III colon cancer is approximately 5% and 15%, indicating the need for optimization for risk stratification and patient selection. Several studies have revealed that current clinicopathological factors lack precision. Circulating tumor DNA (ctDNA) is cell-free DNA originating from cancer cells and can be detected even in the absence of radiologically detectable disease among patients with colon cancer. Recent cohort studies revealed that ctDNA is one of the most significant prognostic factors for patients with early-stage colon cancer, surpassing pathological and clinical risk factors. Prospective cohort studies also suggest there may be a predictive role for ctDNA on the decision for consideration of adjuvant therapy. Currently, randomized clinical trials are enrolling to better define this role. In this review article, we review recent literature on ctDNA and its role in patients with colon cancer. We also elaborate on the future clinical utility of ctDNA in clinical practice and the unmet need for research to optimize currently available ctDNA assays.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251317094"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11770762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047976","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Dosimetry and Biological Risk Assessment of Lung Oligometastasis SBRT: VMAT, Helical Tomotherapy, and CyberKnife.","authors":"Zhenjiong Shen, Mingyuan Pan, Lan Sun, Aihui Feng, Yanhua Duan, Hengle Gu, Yan Shao, Hua Chen, Hao Wang, Ying Huang, Zhiyong Xu","doi":"10.1177/15330338251330781","DOIUrl":"10.1177/15330338251330781","url":null,"abstract":"<p><p>PurposeTo compare the dosimetry and biological risk of volumetric modulated arc therapy (VMAT), helical tomotherapy (HT) and cyberKnife (CK) in the treatment of lung oligometastases.Methods and materialsThis retrospective study included a cohort of 21 lung oligometastasis patients, each with 2 or 3 lesions, who had previously undergone stereotactic body radiation therapy (SBRT). VMAT, HT and CK plans were made for each patient. The dose distribution of planning target volume (PTV) and organs at risk (OARs) were evaluated. Three biological risks were evaluated, namely radiation pneumonitis (RP), coronary artery disease (CAD) and congestive heart failure (CHF). Monitor Units (MUs) and beam-on-time were also recorded.ResultsAll techniques were able to produce clinically deliverable plans. The expected biological risks for VMAT plans, CK plans, and HT plans were 6.69%, 5.05%, 5.88% for RP, 1.20%, 1.15%, and 1.17% for CAD, 1.26%, 1.19%, and 1.22% for CHF. The expected risks of RP were slightly lower in CK plans compared to VMAT and HT plans (p < 0.001), with VMAT plans showing the highest expected risks. For central lung cancer, the expected CAD risks of CK and HT plans were lower than those of VMAT plans (p < 0.05). The delivery efficiency of VMAT plans was significantly higher than that of CK plans and HT plans.ConclusionsAll three techniques, VMAT, HT, and CK, meet the therapeutic requirements for target coverage and dose constraints for OARs. Although there are statistical differences, the difference between the expected risk values of RP and CAD is very small, so the clinical manifestations may not show differences.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251330781"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11951914/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143731681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}